Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate

Alimentary Pharmacology & Therapeutics
C J GaveyR E Pounder

Abstract

Bismuth concentration was measured in plasma, dried leucocytes and urine in nine patients before, during and after treatment with tripotassium dicitrato bismuthate (De-Noltab 2 b.d.) for 6 weeks. During treatment there was an 8.5-fold rise in median plasma bismuth concentration (P less than 0.01), a non-significant doubling of leucocyte bismuth content, and a 349-fold rise in 24-h urinary bismuth excretion (P less than 0.01). The significantly increased urinary bismuth excretion continued for at least 3 months after cessation of treatment with tripotassium dicitrato bismuthate, indicating accumulation of bismuth during treatment with this drug.

References

Sep 1, 1976·The Analyst·R C Rooney
May 21, 1988·Lancet·M R Lane, S P Lee
Jan 1, 1988·Annals of Internal Medicine·C P Dooley, H Cohen
Jan 1, 1987·Digestion·G Bianchi PorroW R Cortvriendt
Jan 1, 1988·Gastroenterology·J G Bartlett
Jan 1, 1987·Digestion·J P Bader
May 1, 1980·Clinical and Experimental Pharmacology & Physiology·S P LeeA C Clarke

❮ Previous
Next ❯

Citations

Jan 1, 1992·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·T P KemmerH Ditschuneit
Aug 1, 1994·Alimentary Pharmacology & Therapeutics·H L WaldumA K Sandvik
Feb 1, 1994·Alimentary Pharmacology & Therapeutics·C U NwokoloD E Loft
May 1, 1993·Scandinavian Journal of Gastroenterology·S J RuneM Vilien
Mar 13, 2012·Alimentary Pharmacology & Therapeutics·L PacificoC Chiesa
Oct 1, 1991·Alimentary Pharmacology & Therapeutics·E J PrewettR E Pounder
Apr 11, 1991·The New England Journal of Medicine·W L Peterson
Feb 1, 1989·Alimentary Pharmacology & Therapeutics·C U NwokoloR E Pounder
Apr 1, 1990·Alimentary Pharmacology & Therapeutics·C U NwokoloR E Pounder
Aug 29, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Lingye ZhangShutian Zhang
May 4, 1990·Klinische Wochenschrift·R RaedschJ Blessing
Sep 1, 1989·Medical Toxicology and Adverse Drug Experience·A Slikkerveer, F A de Wolff
Feb 1, 1992·Alimentary Pharmacology & Therapeutics·J G Penston, K G Wormsley
Apr 9, 2002·Human & Experimental Toxicology·D NewtonN D Priest
Oct 1, 1990·British Journal of Clinical Pharmacology·C U Nwokolo, R E Pounder
Apr 1, 1994·Alimentary Pharmacology & Therapeutics·A G FraserR E Pounder
Jan 1, 1991·Scandinavian Journal of Gastroenterology. Supplement·L Z Benet
Jun 26, 1999·Alimentary Pharmacology & Therapeutics·C J Hawkey
Apr 1, 1995·Human & Experimental Toxicology·L A NoachB W Ongerboer de Visser

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.